Studies on patient isolates of HIV-1 have correlated different patterns of cytotropism and virulence with the sero-positive pre-AIDS and AIDS phases of disease. Here we propose to study the evolution of HIV-1 envelope glycoproteins with respect to antibody responses. Two approaches will be used. (i) Viruses representing different phases of infection will be tested for relative susceptibility to neutralization by a panel of antibodies. (ii) Env-encoding sequences from the same viruses will be evaluated for their ability to raise neutralizing antibody. Envs to be studied will include Envs with different V3 loops or growth characteristics, serial Envs representing the progression from the healthy sero-positive to the AIDS phase of infection, and serial Envs from patients with long term non-progressive disease. Antibodies will be raised using a novel method of immunization that we have helped pioneer - gene gun delivery of Env-encoding plasmid DNA to the epidermis. These studies should contribute to the development of vaccines that control viruses representing different phases of infection. They should also resolve the extent to which neutralizing antibody plays a role in the selection of envelope phenotypes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI034241-04
Application #
2003952
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1993-11-15
Project End
1997-12-31
Budget Start
1996-11-01
Budget End
1997-12-31
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Pathology
Type
Schools of Medicine
DUNS #
660735098
City
Worcester
State
MA
Country
United States
Zip Code
01655
Robinson, H L; Pertmer, T M (2000) DNA vaccines for viral infections: basic studies and applications. Adv Virus Res 55:Jan-74
Robinson, H L; Montefiori, D C; Johnson, R P et al. (2000) DNA priming and recombinant pox virus boosters for an AIDS vaccine. Dev Biol (Basel) 104:93-100
Robinson, H L; Montefiori, D C; Johnson, R P et al. (1999) Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5:526-34
Robinson, H L (1999) DNA vaccines: basic mechanism and immune responses (Review). Int J Mol Med 4:549-55
Richmond, J F; Lu, S; Santoro, J C et al. (1998) Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 72:9092-100
Lu, S; Wyatt, R; Richmond, J F et al. (1998) Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 14:151-5
Robinson, H L (1997) DNA vaccines for immunodeficiency viruses. AIDS 11 Suppl A:S109-19
Lu, S; Manson, K; Wyand, M et al. (1997) SIV DNA vaccine trial in macaques: post-challenge necropsy in vaccine and control groups. Vaccine 15:920-3
Robinson, H L; Torres, C A (1997) DNA vaccines. Semin Immunol 9:271-83
Richmond, J F; Mustafa, F; Lu, S et al. (1997) Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology 230:265-74

Showing the most recent 10 out of 13 publications